AXIM BIOTECHNOLOGIES, INC.— Sankey Diagram
Annual mode · period ending 2024-06-30 · SEC EDGAR
FY2024 - Q4(Apr 24 · May 24 · Jun 24)
Total Assets
$4M
↓-12.2% -$519Kvs FY2023
Total Liabilities
$13M
↓-5.2% -$734Kvs FY2023
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2024 | FY2023 |
|---|---|---|
| Total Assets | $4M | $4M |
| Current Assets | $20K | $97K |
| Cash | $0 | $0 |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $20K | $97K |
| Non-Current Assets | $4M | $4M |
| PPE | $118K | $78K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $4M |
| Investments | $0 | $0 |
| Other Non-Current | $4M | $279K |
| Total Liab+Eq | $4M | $4M |
| Current Liab. | $7M | $8M |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $233K | $318K |
| Other CL | $6M | $8M |
| Non-Current Liab. | $7M | $6M |
| Long-Term Debt | $6M | $0 |
| Other LT Liab. | $724K | $6M |
| Equity | $-10M | $-10M |
| Retained Earnings | $75M | $71M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · AXIM · Comparing FY2024 vs FY2023